Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Progressive Digital Media Group PLC       GB00B1GCQP32

PROGRESSIVE DIGITAL MEDIA GROUP PLC
Mes dernières consult.
Most popular
  Report  
SummaryNewsCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsSector newsTweets

GlobalData : Type 2 diabetes market to more than double, to $64 billion by 2026

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/11/2017 | 12:27pm CET

The type 2 diabetes space across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, is set to more than double in value from $26.8 billion in 2016 to around $64 billion by 2026. While the global T2D market is crowded with inexpensive generics and marked by a late-stage pipeline filled with me-too drugs, the market is expected to grow at a strong compound annual growth rate of 8.4%, according to research and consulting firm GlobalData.

The company's latest report reveals that the dramatic increase in the prevalence, progressive nature and diagnosis of type 2 diabetes is the main driver of this rapid growth rate. The rise in disease-related comorbidities has also fuelled a more aggressive approach to treatment, including the use of multiple-drug therapies.

Current and future leaders in the type 2 diabetes space during the forecast period include Novo Nordisk, Astra Zeneca, Merck, Eli Lilly/BI, Takeda, Johnson & Johnson, Sanofi, and Intarcia Therapeutics. All of these companies have either late-stage pipeline products or very recently marketed products that have the potential to significantly strengthen their company's portfolios.

Jesus Cuaron, Ph.D., PPM, Managing Healthcare Analyst at GlobalData, explains: 'All currently available treatments for type 2 diabetes are initially effective and reduce complication rates, but they lack the ability to maintain glycemic control in the long term because of the progressive nature of pancreatic β-cell dysfunction. This represents one of the highest unmet needs in the type 2 diabetes space and demonstrates that the market has a significant growth opportunity for new patent-protected products that successfully address underlying disease pathology, cardiovascular concerns, or compliance issues.'

Overall, the ever-increasing prevalence of diabetes, along with the increased usage of anti-diabetic drugs with non-glycemic benefits, will lead to significant growth of the type 2 diabetes market.

- Information based on GlobalData's report: PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026.

GlobalData plc published this content on 11 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 11 August 2017 10:26:08 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PROGRESSIVE DIGITAL MEDIA
02/22GLOBALDATA : Mobile wallet is gradually displacing cash in India, says GlobalDat..
PU
02/22GLOBALDATA : Australia’s foodservice profit sector to surpass AUD$80bn by ..
PU
02/21GLOBALDATA : Internet and tech giants, not banks, are the darlings of Fintech ex..
PU
02/21GLOBALDATA : Asia-Pacific presents growth opportunities for UnionPay, says Globa..
PU
02/21GLOBALDATA : Australian smoking tobacco market to grow in short term despite tax..
PU
02/20GLOBALDATA : Consumer-centric businesses rule VC funding, but are they making mo..
PU
02/20GLOBALDATA : Systems integration contracts dominate IT services deals in India, ..
PU
02/20GLOBALDATA : Australia’s NPP opens road for QR payment, says GlobalData
PU
02/19GLOBALDATA : Late-stage CKD-induced comorbidity therapeutics market to reach $10..
PU
02/19GLOBALDATA : Enterprises are evolving their cyber security needs to combat incre..
PU
More news
Financials ( GBP)
Sales 2017 118 M
EBIT 2017 -
Net income 2017 -
Debt 2017 33,4 M
Yield 2017 1,41%
P/E ratio 2017 -
P/E ratio 2018 -
Capi. / Sales 2017 5,01x
Capi. / Sales 2018 -
Capitalization 559 M
Income Statement Evolution
Managers
NameTitle
Michael Thomas Danson Chief Executive Officer
Bernard Anthony Cragg Chairman
Graham Charles Lilley Chief Financial Officer & Secretary
Peter Martin Harkness Independent Non-Executive Director
Murray Legg Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
PROGRESSIVE DIGITAL MEDIA GROUP PLC776
S&P GLOBAL INC10.92%47 627
RELX N.V.-9.99%43 917
RELX-12.45%43 868
THOMSON REUTERS CORP-8.01%28 152
EQUIFAX-2.01%13 669